Fighting Ebola: Voices from the Frontline Documenting the Experiences of East African Deployed Experts Who Volunteered to Fight Ebola in West Africa Implemented By
Total Page:16
File Type:pdf, Size:1020Kb
Load more
Recommended publications
-
Targeting Ebola 2015
Agenda of Targeting Ebola 2015 May 28-29, 2015 Institut Pasteur - Paris, France www.targeting-ebola.com Welcome Note On behalf of the Targeting Infectious Diseases Committee, the Institut Pasteur, the COPED and the Task Force for Ebola in France, it is our pleasure to announce the organization of the International Congress on Targeting Ebola 2015 which will be held on May 28-29, 2015 at Pasteur Institute, Paris, France. The World Health Organization (WHO) was notified on March 23, 2014, of an outbreak of EVD in Guinea. The disease soon spread to the bordering countries of Liberia and Sierra Leone, which are the most severely affected countries. On August 8, 2014, the epidemic was declared a “public health emergency of international concern” (WHO Ebola Response Team, NEJM 2014, 371, 1481). Suspected cases of EVD have since been reported in seven affected countries (Guinea, Liberia, Nigeria, Senegal, Sierra Leone, Spain, and the United States of America). Unprecedented in scale and geographical distribution since the identification of Ebola in 1976, the current epidemic has an apparent overall case-fatality ratio of about 70%; but it is suspected that many more cases have gone unrecorded. On May 2015, more than 10.000 deaths and 30.000 cases had been reported in Sierra Leone, Liberia and Guinea, according to the WHO. Globally, the situation is improving. The epidemic is over in Liberia, however in Guinea and Sierra Leone, the initial decline observed a few weeks ago is stable with approximately 20 new cases / week. The vast majority of cases are reported from the western prefecture of Forecariah, which borders the Sierra Leonean district of Kambia. -
Clinical Trial Protocol Sponsored by OCRPRO
PREVAIL IV: Double-blind, Randomized, Two-phase, Placebo-controlled, Phase II Trial of GS-5734 to Assess the Antiviral Activity, Longer-term Clearance of Ebola Virus, and Safety in Male Ebola Survivors with Evidence of Ebola Virus Persistence in Semen NIAID Protocol Number: 16-I-N137 Version Number: 10.0 Date: May 13, 2019 Investigational New Drug (IND) Number: 130621 IND Sponsor: Office of Clinical Research Policy and Regulatory Operations (OCRPRO), Division of Clinical Research (DCR), National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH) Local Liberian Medical Officer: Ian Wachekwa, MD Safety Medical Officer John F. Kennedy Hospital 21 Street, Sinkor Monrovia, Liberia [email protected] (t) +231880890907 Sponsor Medical Monitor: Alan Lifson, MD, MPH Professor, Division of Epidemiology and Community Health School of Public Health University of Minnesota 1300 S. Second St., Ste. 300 Minneapolis, MN 55454 (t) 612-626-9697 (f) 612-624-0315 [email protected] Pharmaceutical Support Provided by: Gilead Sciences, Inc. PREVAIL IV Version 10.0 13 May 2019 Conducted by: Liberia-US Joint Clinical Research Partnership also known as the Partnership for Research on Ebola Virus in Liberia (PREVAIL) Page 2 of 77 PREVAIL IV Version 10.0 13 May 2019 Key Roles NIH Principal Investigator: Elizabeth S. Higgs, MD, MIA, DTMH Division of Clinical Research, NIAID [email protected] (c) +301-768-3947 skype: libby.higgs2 Liberian Principal Investigator: Dehkontee Gayedyu-Dennis, MD PREVAIL [email protected] (t) +231-886-538-810 -
Chapter 1 BEFORE EBOLA
10/12/2017 Preparing for a Crisis: Lessons Learned at Emory Before, During, and After Ebola Jay B. Varkey, MD On behalf of the Chapter 1 BEFORE EBOLA 2 1 10/12/2017 The Story of Emile Meliandou, Guinea, December 2013 Photograph by Suzanne Beukes, UNICEF The Story of Emile Meliandou, Guinea, December 2013 AM Saéz et al, EMBO Mole Med 2015 2 10/12/2017 The Story of Emile Meliandou, Guinea, December 2013 The Story of Emile Meliandou, Guinea, December 2013 AM Saéz et al, EMBO Mole Med 2015 3 10/12/2017 The Story of Emile Meliandou, Guinea, December 2013 Photograph by Suzanne Beukes, UNICEF Spread of a “Cholera‐Like Illness” MeliandouConakry, 12/2013 – 3/2014 S Baize, N Engl J Med 2014 4 10/12/2017 Ebola Virus Disease (EVD) Spread to Liberia and Sierra Leone 4/2014 ELWA Ebola Treatment Unit (ETU) Monrovia, Liberia 6/2014 – 7/2014 Photograph by Bethany Fankhauser, SIM 5 10/12/2017 ELWA ETU Monrovia, Liberia 6/2014 – 7/2014 Photograph by Bethany Fankhauser, SIM ELWA ETU Monrovia, Liberia July 2014 • 40 patients with EVD treated • 39 of 40 died • July 22‐23: 2 American humanitarians working in the ELWA ETC develop a fever…. • Initially treated for malaria • Laboratory testing confirmed Ebola Virus Disease 6 10/12/2017 Ebola Virus Disease and Emory July 30, 2014 • Emory University Hospital was asked to receive the first patients with confirmed Ebola virus disease to be treated in the United States • 2 American humanitarians had become infected while working in an ETU in Monrovia, Liberia • Patient 1: 33 yo male physician • Patient 2: 59 yo female medical missionary • Expected arrival time unclear but Emory was asked to be ready to receive the 1st patient within 72 hours. -
One Health Workforce Project
One Health Workforce Project John Deen One Health Workforce Project Part of USAID’s EPT2 Program Emerging Threats Program Emerging Threats Program Each civil society needs the capacity and confidence to defend itself Emerging Threats Program Invasion by pathogens • Significant death and morbidity • Large amount of disruption – Health system – Economy – Agriculture – Trade – Politics • Large influx of aid is also disruptive • A breakdown in civil society Emerging Threats Program Factors for Human Disease Emergence . 1415 species of infectious agents reported to cause disease in humans . Viruses, prions, bacteria, rickettsia, fungi, protozoa, helminths . 868/1415 (61%) zoonotic . 175 emerging infectious diseases . 132/175 (75%) emerging zoonoses Taylor et al. Risk factors for disease emergence. 2001, Philosophical Transactions, The Royal Society, London Emerging Threats Program Human Cases One Health – Public health Wild Animal Domestic Animal as part of a larger “ecosystem” Animal Amplification C A Wildlife Surveillance/ S Forecasting Early Detection Control E Opportunity S Human Amplification TIME Which predicts a country’s susceptibility to a pathogen? Agent or Host? Emerging Threats Program Eg Ebola • The presence of the agent (R0 <2) • The presence of a host defense (Workforce plus government capacity) Emerging Threats Program National One Health Workforce • Competent • Inspired • Empowered To • Prevent • Detect • Respond Emerging Threats Program History • SARS IHR aim of 100% of countries compliant • Ebola, MERS IHR at 32%, PVS lower -
Lessons for the Future
Lessons for the Future What East African experts learned from fighting the Ebola epidemic in West Africa A regional conference with international participation held in Nairobi, Kenya from 6th to 8th November 2017 Lessons for the Future What East African experts learned from fighting the Ebola epidemic in West Africa A regional conference with international participation held in Nairobi, Kenya from 6th to 8th November 2017 Conference Report Implemented by: Contents List of Abbreviations . 5 Foreword . 7 Summary . 8 Introduction . 9 East joins West in the fight against Ebola . 10 A wealth of experience . 11 Objectives of the conference . 11 Conference methodology and brief programme overview . 12 Voices from the Ebola frontline: Documenting a treasure trove of experience . 12 Day one: Welcoming delegates to Kenya . 16 Opening speech by Dr Monica Musenero . 17 Germany’s experiences of establishing a database of rapidly deployable experts . 19 First sharing of experiences . 20 Exploring eight themes . 20 The first four pre-set themes . 21 The four themes subsequently chosen by the participants . 21 Theme 1: Being ready at short notice – establishing a pool of deployable experts . 22 What worked well? . 22 What did not work well? . 22 Lessons learned . 24 Recommendations . .. 24 Theme 2: Taking informed decisions – effective communication to mitigate risks and crises . 25 What worked well? . 25 What did not work well? . 25 Lessons learned . 27 Recommendations . .. 28 Theme 3: Working together - One Health . .28 What worked well? . 28 What did not work well? . 29 Lessons learned . 29 Recommendations . .. 30 Theme 4: Effective logistics – what, where, when and how? . 31 What worked well? . -
Kinase Inhibitors and Nucleoside Analogues As Novel Therapies to Inhibit HIV-1 Or ZEBOV Replication
Kinase Inhibitors and Nucleoside Analogues as Novel Therapies to Inhibit HIV-1 or ZEBOV Replication by Stephen D. S. McCarthy A thesis submitted in conformity with the requirements for the degree of Doctor of Philosophy Department of Laboratory Medicine and Pathobiology University of Toronto © Copyright by Stephen D. S. McCarthy (2017) Kinase Inhibitors and Nucleoside Analogues as Novel Therapies to Inhibit HIV-1 or ZEBOV Replication Stephen D.S. McCarthy Doctor of Philosophy Graduate Department of Laboratory Medicine and Pathobiology University of Toronto 2017 Abstract Without a vaccine for Human Immunodeficiency Virus type 1 (HIV-1), or approved therapy for treating Zaire Ebolavirus (ZEBOV) infection, new means to treat either virus during acute infection are under intense investigation. Repurposing tyrosine kinase inhibitors of known specificity may not only inhibit HIV-1 replication, but also treat associated inflammation or neurocognitive disorders caused by chronic HIV-1 infection. Moreover, tyrosine kinase inhibitors may effectively treat other infections, including ZEBOV. In addition, established nucleoside/nucleotide analogues that effectively inhibit HIV-1 infection, could also be repurposed to inhibit ZEBOV replication. In this work the role of two host cell kinases, cellular protoncogene SRC (c-SRC) and Protein Tyrosine Kinase 2 Beta (PTK2B), were found to have key roles during early HIV-1 replication in primary activated CD4+ T-cells ex vivo. siRNA knockdown of either kinase increased intracellular reverse transcripts and decreased nuclear proviral integration, suggesting they act at the level of pre-integration complex (PIC) formation or PIC nuclear translocation. c-SRC siRNA knockdown consistently reduced p24 levels of IIIB(X4) and Ba-L(R5) infection, or luciferase ii activity of HXB2(X4) or JR-FL(R5) recombinant viruses, prompting further drug inhibition studies of this kinase. -
A Case-Study Approach to Investigate Transmission, Co-Infection, And
Louisiana State University LSU Digital Commons LSU Doctoral Dissertations Graduate School 5-20-2019 A Case-study Approach to Investigate Transmission, Co-infection, and Clinical Sequelae During Epidemics of Dengue and Ebola Virus Disease Jennifer Elizabeth Giovanni [email protected] Follow this and additional works at: https://digitalcommons.lsu.edu/gradschool_dissertations Part of the Clinical Epidemiology Commons, Epidemiology Commons, Immunology of Infectious Disease Commons, International Public Health Commons, and the Virology Commons Recommended Citation Giovanni, Jennifer Elizabeth, "A Case-study Approach to Investigate Transmission, Co-infection, and Clinical Sequelae During Epidemics of Dengue and Ebola Virus Disease" (2019). LSU Doctoral Dissertations. 4931. https://digitalcommons.lsu.edu/gradschool_dissertations/4931 This Dissertation is brought to you for free and open access by the Graduate School at LSU Digital Commons. It has been accepted for inclusion in LSU Doctoral Dissertations by an authorized graduate school editor of LSU Digital Commons. For more information, please [email protected]. A CASE-STUDY APPROACH TO INVESTIGATE TRANSMISSION, CO-INFECTION, AND CLINICAL SEQUELAE DURING EPIDEMICS OF DENGUE AND EBOLA VIRUS DISEASE A Dissertation Submitted to the Graduate Faculty of the Louisiana State University and Agricultural and Mechanical College in partial fulfillment of the requirements for the degree of Doctor of Philosophy in The Department of Pathobiological Sciences by Jennifer Elizabeth Giovanni B.S., Missouri -
UNIPH Epidemiological Bulletin
MINISTRY OF HEALTH UGANDA Epidemiological Bulletin UNIPH Volume 1| Issue 2 | Dec 2016 Quarterly Epidemiological Bulletin of the Uganda National Institute of Public Health, Ministry of Health October—December 2016 EDITORIAL TEAM Dr Monica Musenero | Dear Reader, ACHS , Epidemiology & Surveillance Division, MoH Welcome to the 5th edition, Issue 2 Volume 1 of the Uganda Dr Immaculate Nabukenya | National Institute Public Health (UNIPH) Quarterly Epidemio- logical Bulletin. ACHS, Veterinary Public Health, MoH This bulletin aims to inform the district, national, and global Dr Alex Riolexus Ario | stakeholders on the public health interventions, evaluation of Field Coordinator, Uganda Public Health Fellowship surveillance systems and outbreak investigations undertaken in Program, Uganda National Institute of Public Health, disease prevention and control by Ministry of Health. MoH In this issue, we present highlights on evaluation of surveillance system in emergence setting, chemical poisoning due to con- Ms Leocadia Kwagonza | sumption of a dead pig, chemical poisoning in a flower farm and PHFP-FET, Fellow, Uganda Cancer Institute (UCI) Typhoid misdiagnosis among others. These studies generated evidence and results which will be used to inform planning and Ms Joy Kusiima interventions in the country and beyond. PHFP-FET Fellow, Uganda Cancer Institute (UCI) For any further information regarding the articles, feel free to Ms Claire Birabawa contact us at: [email protected] OR lkwagon- [email protected] PHFP-FET Fellow, Division of Health Information, We will appreciate any feedback regarding the content and gen- MoH eral outlook of this issue and look forward to hearing from you. Dr Phoebe Hilda Alitubeera We hope this will be both an informative and enjoyable reading for you. -
Exposure to Ebola Virus and Risk for Infection with Malaria Parasites, Rural Gabon Jessica L
Exposure to Ebola Virus and Risk for Infection with Malaria Parasites, Rural Gabon Jessica L. Abbate, Pierre Becquart, Eric Leroy, Vanessa O. Ezenwa,1 Benjamin Roche1 diseases (1) and the high frequency of Plasmodium An association between malaria and risk for death spp. co-infection among patients undergoing treat- among patients with Ebola virus disease has suggested ment for confirmed EVD 2( ). At the individual level, within-host interactions between Plasmodium falciparum parasites and Ebola virus. To determine whether such several retrospective epidemiology studies of pa- an interaction might also influence the probability of ac- tients undergoing treatment for confirmed EVD have quiring either infection, we used a large snapshot sur- attempted to determine whether concurrent malaria veillance study from rural Gabon to test if past exposure affects patient outcomes. In Sierra Leone (3) and at to Ebola virus is associated with current infection with 1 Ebola treatment center in Liberia (4), mortality risk Plasmodium spp. during nonepidemic conditions. We was much higher among Ebola patients who were co- found a strong positive association, on population and infected with Plasmodium parasites than among pa- individual levels, between seropositivity for antibodies tients who were not co-infected, and a study in Guin- against Ebola virus and the presence of Plasmodium ea found that adverse outcomes were higher among parasites in the blood. According to a multiple regres- EVD patients with higher P. falciparum parasite loads sion model accounting for other key variables, antibodies than among those with lower levels of parasitemia (5). against Ebola virus emerged as the strongest individual- level risk factor for acquiring malaria. -
Quarantine Sierra Leone
QUARANTINE IN SIERRA LEONE Lessons Learned On the use of quarantine in Sierra Leone as a support measure during the Ebola Epidemic 2014-2015 Laura Sustersic for Welthungerhilfe Sierra Leone Freetown April 2015 TABLE of CONTENTS 1. INTRODICTION 3 1.1 THE CONTEXT: EBOLA EPIDEMICS IN HISTORY 4 2. BRIEF OVERVIEW OF OUTBREAK AND WHH ENGAGEMENT 5 3. PRINCIPLES AND USE OF QUARANTINE FOR EBOLA CONTAINMENT 6 3.1 PUBLIC HEALTH PRINCIPLES AND INFECTIOUS DISEASES 6 3.2 PRINCIPLES OF EBOLA CONTAINMENT 6 3.3 MONITORING OF CONTACTS 7 3.4 CHOOSING QUARANTINE IN SIERRA LEONE 8 4. IMPLEMENTING GOOD QUARANTINES IN SIERRA LEONE 10 4.1 HHQ, FLOW CHART WITH STAKEHOLDERS 11 4.2 ELEMENTS TO IMPLEMENT SUCCESSFUL HOUSEHOLDS QUARANTINE 12 4.2.1 CONTACT TRACING 12 4.2.2 RESPECTING BASIC HUMAN RIGHTS 12 4.2.3 RECOGNIZING ROLES AND RESPONSIBILITIES OF INDIVIDUALS IN QUARANTINE 13 4.2.4 COMMUNITY SUPPORT 13 4.2.5 SECURITY 13 4.3 PROBLEMS ASSOCIATED WITH QUARANTINE 14 4.3.1 ISSUES WITH OTHER RESPONSE PILLARS 15 4.3.2 SHORTCOMINGS IN QUARANTINE SUPPORT SERVICES 15 4.3.4 ISSUES DIRECTLY RELATED TO QUARANTINE 16 4.3.5 ISSUES TO BE VERIFIED OR FURTHER DISCUSSED 16 4.4 SPECIAL CASE OF QUARANTINE IN SLUMS 16 5. LESSONS LEARNED 17 6. CONCLUSIONS 18 ANNEX 1-EBOLA OUTBREAK IN SIERRA LEONE 19 DERC District Ebola Response Centre EVD Ebola Virus Disease HH Households MoHS Min. of Health and Sanitation MSF Medicines Sans Frontières NERC National Ebola Response Centre NFI Non Food Items Q Quarantine SOP Standard Operating Procedures UNMEER UN Mission for Ebola Emergency Response VIP Ventilated Improved Pit-latrines WA Western Area District WASH Water, Sanitation and Hygiene WHH Welthungerhilfe WHO World Health Organization 2 1. -
February 2020 Vol 26, No 2, February 2020
® February 2020 Purchase and partial gift from the Catherine and Ralph Benkaim Collection; Severance and Greta Millikin Purchase Fund. Public domain digital image courtesy of The Cleveland Museum of Modern Art, Cleveland, Ohio Cleveland, Art, Modern of Museum Cleveland The of courtesy image digital domain Public Fund. Purchase Millikin Greta and Severance Collection; Benkaim Ralph and Catherine the from gift partial and Purchase Opaque watercolor, ink, and gold on paper. 10 1/4 in x 6 15/16 in/26 cm x 17.6 cm. cm. 17.6 x cm in/26 15/16 6 x in 1/4 10 paper. on gold and ink, watercolor, Opaque , Possibly Maru Ragini from a Ragamala, 1650–80. 1650–80. Ragamala, a from Ragini Maru Possibly , A Rajput Warrior with Camel with Warrior Rajput A Artist Unknown. Unknown. Artist Coronaviruses Vol 26, No 2, February 2020 EMERGING INFECTIOUS DISEASES Pages 191–400 DEPARTMENT OF HEALTH & HUMAN SERVICES Public Health Service Centers for Disease Control and Prevention (CDC) Mailstop D61, Atlanta, GA 30329-4027 Official Business Penalty for Private Use $300 Return Service Requested ISSN 1080-6040 Peer-Reviewed Journal Tracking and Analyzing Disease Trends Pages 191–400 EDITOR-IN-CHIEF D. Peter Drotman ASSOCIATE EDITORS EDITORIAL BOARD Charles Ben Beard, Fort Collins, Colorado, USA Barry J. Beaty, Fort Collins, Colorado, USA Ermias Belay, Atlanta, Georgia, USA Martin J. Blaser, New York, New York, USA David M. Bell, Atlanta, Georgia, USA Andrea Boggild, Toronto, Ontario, Canada Sharon Bloom, Atlanta, Georgia, USA Christopher Braden, Atlanta, Georgia, USA Richard Bradbury, Melbourne, Australia Arturo Casadevall, New York, New York, USA Mary Brandt, Atlanta, Georgia, USA Kenneth G. -
Post‑Ebola Syndrome: the Silent Outbreak
Expert Commentary Reflections on the Ebola Public Health Emergency of International Concern, Part 1: Post‑Ebola Syndrome: The Silent Outbreak Following the most recent outbreak of Ebola virus disease (EVD), disorders (18%), and depression (17%).[7] A small proportion the organized global effort brought new capabilities to of patients reported various other neurological complaints, postoutbreak clinical monitoring and surveillance. This, in including “tremors,” hemiparesis, and focal (e.g., facial) turn, permitted a more robust analysis of post-EVD sequelae, nerve palsies.[6] A recent report also suggests that late-onset resulting in better understanding of the so-called post-EVD encephalitis and polyarthritis can be seen among EVD syndrome (PEVDS).[1] Although it was previously established survivors.[12] that PEVDS exists, factors affecting its duration and severity [2] were not well known. The pathogenesis of PEVDS was, and NEUROLOGIC MANIFESTATIONS continues to be, poorly understood.[2] This knowledge gap A broad range of neurologic conditions has been reported in is being addressed through a joint Liberia-US Partnership association with PEVDS.[13] The exact relationship remains for Research on Ebola Virus in Liberia (PREVAIL) that was poorly understood, with some investigators suggesting established in 2014.[3] PREVAIL will track 1500 survivors that central nervous system (CNS) manifestations may be for up to 5 years to catalog long-term problems and try to associated with factors such as cerebral hypoperfusion due to better elucidate why individuals previously infected remain shock, viral encephalitis, or post-EVD encephalomyelitis.[13] capable of transmitting the disease. It is now known at It is likely that more than one factor is involved.